Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMLXNASDAQ:HRTXNASDAQ:NGNENYSE:OSTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMLXAmylyx Pharmaceuticals$3.91+4.8%$3.53$1.58▼$7.27$268.02M-0.511.48 million shs1.34 million shsHRTXHeron Therapeutics$2.41+5.2%$1.82$1.04▼$3.93$367.12M1.551.88 million shs1.76 million shsNGNENeurogene$17.78+0.6%$18.04$14.42▼$74.49$264.12M1.01210,282 shs119,358 shsOSTXOS Therapies$1.68+4.3%$2.60$1.41▼$7.00$36.57MN/A551,132 shs93,494 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMLXAmylyx Pharmaceuticals+4.83%+16.37%+4.55%-11.34%+13.66%HRTXHeron Therapeutics+5.24%+0.42%+45.18%+50.63%+2.12%NGNENeurogene+0.62%+5.14%-5.88%-20.39%-51.07%OSTXOS Therapies+4.35%+0.60%-11.58%-62.33%+167,999,900.00%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMLXAmylyx Pharmaceuticals2.9119 of 5 stars3.41.00.00.03.03.31.3HRTXHeron Therapeutics3.8677 of 5 stars3.50.00.04.23.91.70.6NGNENeurogene2.2808 of 5 stars3.61.00.00.04.00.80.6OSTXOS Therapies1.6549 of 5 stars3.80.00.00.00.60.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMLXAmylyx Pharmaceuticals 2.71Moderate Buy$7.3387.55% UpsideHRTXHeron Therapeutics 3.00Buy$5.67135.13% UpsideNGNENeurogene 3.13Buy$60.83242.14% UpsideOSTXOS Therapies 3.50Strong Buy$17.50941.67% UpsideCurrent Analyst Ratings BreakdownLatest OSTX, HRTX, AMLX, and NGNE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/5/2025AMLXAmylyx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.002/28/2025HRTXHeron TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.002/20/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.001/30/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.001/16/2025OSTXOS TherapiesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $15.001/15/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00(Data available from 3/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMLXAmylyx Pharmaceuticals$87.37M3.07$0.71 per share5.51$6.42 per share0.61HRTXHeron Therapeutics$144.29M2.54N/AN/A($0.23) per share-10.48NGNENeurogene$925K285.54N/AN/A$14.51 per share1.23OSTXOS TherapiesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMLXAmylyx Pharmaceuticals$49.27M-$4.44N/AN/AN/AN/A-36.97%-29.61%5/8/2025 (Estimated)HRTXHeron Therapeutics-$110.56M-$0.09N/AN/AN/A-20.31%N/A-12.72%5/6/2025 (Estimated)NGNENeurogene-$36.32MN/A0.00N/AN/AN/A-32.81%-27.96%3/17/2025 (Estimated)OSTXOS Therapies-$7.79MN/A0.00N/AN/AN/AN/A-569.57%N/ALatest OSTX, HRTX, AMLX, and NGNE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/17/2025N/ANGNENeurogene-$1.10N/AN/AN/AN/AN/A3/4/2025Q4 2024AMLXAmylyx Pharmaceuticals-$0.49-$0.55-$0.06-$0.55N/A($0.67) million2/27/2025Q4 2024HRTXHeron Therapeutics-$0.03$0.02+$0.05$0.02$37.37 million$40.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMLXAmylyx Pharmaceuticals$1.0225.98%N/AN/A N/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/ANGNENeurogeneN/AN/AN/AN/AN/AOSTXOS TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMLXAmylyx PharmaceuticalsN/A4.554.55HRTXHeron TherapeuticsN/A2.281.74NGNENeurogeneN/A9.099.09OSTXOS TherapiesN/A0.760.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMLXAmylyx Pharmaceuticals95.84%HRTXHeron Therapeutics80.01%NGNENeurogene52.37%OSTXOS TherapiesN/AInsider OwnershipCompanyInsider OwnershipAMLXAmylyx Pharmaceuticals11.70%HRTXHeron Therapeutics5.76%NGNENeurogene9.92%OSTXOS TherapiesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMLXAmylyx Pharmaceuticals20068.55 million60.53 millionOptionableHRTXHeron Therapeutics300152.33 million143.33 millionOptionableNGNENeurogene9014.86 million13.38 millionOptionableOSTXOS TherapiesN/A21.77 millionN/AN/AOSTX, HRTX, AMLX, and NGNE HeadlinesRecent News About These CompaniesOS Therapies schedules Scientific Advice Meeting for OST-HER2 in Q3March 11 at 4:42 PM | markets.businessinsider.comSpin-Offs as Catalysts: Unlocking Value, Driving Growth, and Creating Opportunities for Big GainsMarch 4, 2025 | theglobeandmail.comCalidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVFebruary 28, 2025 | accessnewswire.comJoin OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on February 27February 26, 2025 | finance.yahoo.comJoin OS Therapies' Exclusive Live Investor Webinar and Q&A Session on February 27February 26, 2025 | businesswire.comOS Therapies sets up subsidiary to seek ADC joint ventures with US, China peersFebruary 24, 2025 | fiercebiotech.comOS Therapies receives patent notice of allowance for OST-HER2February 20, 2025 | markets.businessinsider.comOS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2February 20, 2025 | businesswire.comOS Therapies Inc (NYSE:OSTX) Major Shareholder Sells $284,000.00 in StockFebruary 19, 2025 | insidertrades.comOSTX Stock Earnings: OS Therapies Reported Results for Q2 2024February 14, 2025 | investorplace.comOS Therapies gears up for FDA meeting on cancer drugFebruary 14, 2025 | msn.comOS Therapies initiates commercial manufacturing of OST-HER2February 14, 2025 | markets.businessinsider.comSmall-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone CancerFebruary 14, 2025 | benzinga.comOS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) FilingFebruary 14, 2025 | businesswire.comOS Therapies gears up for osteosarcoma drug approvalFebruary 4, 2025 | msn.comOS Therapies Provides Corporate UpdateFebruary 4, 2025 | businesswire.comOS Therapies files to sell 10.83M shares of common stock for holdersFebruary 1, 2025 | markets.businessinsider.comWhy OS Therapies Incorporated’s (OSTX) Stock Is Down 25.00%January 30, 2025 | aaii.comOS Therapies Inc trading resumesJanuary 30, 2025 | markets.businessinsider.comOS Therapies Inc (OSTX) Stock: More Strategic Than Meets the EyeJanuary 18, 2025 | bovnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOSTX, HRTX, AMLX, and NGNE Company DescriptionsAmylyx Pharmaceuticals NASDAQ:AMLX$3.91 +0.18 (+4.83%) Closing price 03/12/2025 04:00 PM EasternExtended Trading$3.84 -0.08 (-1.92%) As of 03/12/2025 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Heron Therapeutics NASDAQ:HRTX$2.41 +0.12 (+5.24%) Closing price 03/12/2025 04:00 PM EasternExtended Trading$2.39 -0.02 (-0.83%) As of 03/12/2025 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Neurogene NASDAQ:NGNE$17.78 +0.11 (+0.62%) Closing price 03/12/2025 04:00 PM EasternExtended Trading$17.80 +0.02 (+0.11%) As of 03/12/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.OS Therapies NYSE:OSTX$1.68 +0.07 (+4.35%) Closing price 03/12/2025 04:00 PM EasternExtended Trading$1.65 -0.03 (-1.79%) As of 03/12/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ramaco Resources Pins Hopes on Coal's Untapped Potential Beyond a Market Correction, Moves to Make Now NVIDIA Stock Remains Stunningly Undervalued—Here’s Why Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy 3 Stocks Institutions Are Quietly Dumping Marvell’s 40% Drop Presents a Compelling Buying Opportunity These 3 Dividend Stocks Jumped 15% in a Month—More to Come? Why Wayfair Stock May Be a Hidden Gem for Value Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
